Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
747 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 996
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇨🇳 Mainland ChinaOfficialPayment standards, same-generic-name and VBP linkage, transition arrangements and local implementation2025-12-07 / 2026-01-01Latest observed: 2025-12-07
🇨🇳 Mainland ChinaOfficialOfficial renewal conditions, covered-scope expense basis and regular-directory/renegotiation branches.2026-05-31Latest observed: 2026-05-31
🇨🇳 Mainland China
OfficialOfficial renewal conditions, covered-scope expense basis and regular-directory/renegotiation branches.2026-05-31Latest observed: 2026-05-31
🇨🇳 Mainland ChinaOfficialHistorical consultation-stage explanation; current eligibility, warning thresholds and renewal use the final May 2026 documents.2026-05-09Latest observed: 2026-05-09
🇨🇳 Mainland ChinaOfficialDual-channel definition, supply requirements and medical-insurance payment2021-05-10Latest observed: 2021-05-10
🇨🇳 Mainland ChinaOfficialVBP, provincial listing, payment standards, retail, RWE and price governanceIssued 30 Mar 2026; published 14 Apr 2026Latest observed: 2026-04-14
🇨🇳 Mainland ChinaOfficialFoundation for expert review, negotiation, renewal and payment compliance2020-07-31 / 2020-09-01Latest observed: 2020-07-31
🇨🇳 Mainland ChinaOfficialNational institutional foundation for VBP2021-01-28Latest observed: 2021-01-28
🇨🇳 Mainland ChinaOfficialEntry point for the latest procurement round, participating entities and committed demand2025-09-20Latest observed: 2025-09-20
🇨🇳 Mainland ChinaOfficialClinical-evidence quality, participant protection, proportionate risk management, data reliability and traceability, and sponsor/investigator dutiesAnnounced 21 May 2026; published 8 Jun 2026; effective 1 Sep 2026Latest observed: 2026-06-08
🇨🇳 Mainland ChinaOfficialClinical-evidence quality, participant protection, proportionate risk management, data reliability and traceability, and sponsor/investigator dutiesAnnounced 21 May 2026; published 8 Jun 2026; effective 1 Sep 2026Latest observed: 2026-06-08
🇨🇳 Mainland China
OfficialClinical-evidence quality, participant protection, proportionate risk management, data reliability and traceability, and sponsor/investigator dutiesAnnounced 21 May 2026; published 8 Jun 2026; effective 1 Sep 2026Latest observed: 2026-06-08
🇨🇳 Mainland ChinaOfficialImplementation of payment scope and interpretation of clinical scenarios2026-04-17Latest observed: 2026-04-17
🇨🇳 Mainland ChinaOfficialPolicy status of RWE and boundaries against overstatement2026-01-14Latest observed: 2026-01-14
🇨🇳 Mainland ChinaOfficialMain notices only: eligibility, historic filing dates and local VBP commencement; attachments, renewal formula, selected pack rows and provincial execution not verifiedThree distinct 2026 programme noticesLatest observed: Notices 2026-05-31, 2026-07-31 and 2026-08-06
🇨🇳 Mainland ChinaOfficialMain notices only: eligibility, historic filing dates and local VBP commencement; attachments, renewal formula, selected pack rows and provincial execution not verifiedThree distinct 2026 programme noticesLatest observed: Notices 2026-05-31, 2026-07-31 and 2026-08-06
🇨🇳 Mainland ChinaOfficialMain notices only: eligibility, historic filing dates and local VBP commencement; attachments, renewal formula, selected pack rows and provincial execution not verifiedThree distinct 2026 programme noticesLatest observed: Notices 2026-05-31, 2026-07-31 and 2026-08-06
🇨🇳 Mainland ChinaOfficialMain notices only: eligibility, historic filing dates and local VBP commencement; attachments, renewal formula, selected pack rows and provincial execution not verifiedThree distinct 2026 programme noticesLatest observed: Notices 2026-05-31, 2026-07-31 and 2026-08-06
🇨🇳 Mainland China
Official2026 eligibility, historical filing windows and separate basic/commercial-insurance pathways; planned publication is not a final result.2026-05-31Latest observed: 2026-05-31
🇨🇳 Mainland China
OfficialInitial online filing and evidence-slide requirements; later-stage submission instructions are separate.2026-05-31Latest observed: 2026-05-31
🇨🇳 Mainland China
OfficialEntry, payment-standard floor, supply commitments and price warnings; distinct from volume-based procurement.2026-05-31Latest observed: 2026-05-31
🇨🇳 Mainland China
OfficialCovered-scope expenses, renewal calculations, comparators and implementation; formal rules prevail over explanatory examples.2026-05Latest observed: 2026-05-31
🇨🇳 Mainland ChinaOfficialSelected applicant, review-owner and marketing-certificate provisions; effective1July2020.2020-01-22Latest observed: 2020-03-30
🇨🇳 Mainland ChinaOfficialOfficial government reprint; selected registration and holder provisions. Signed16January2026, effective15May; not all implementing measures reviewed.2026-05-15Latest observed: 2026-01-28
🇨🇳 Mainland ChinaOfficialSeptember results and October agreement signing; no proof of final publication, commencement or stock.2026-10-20Latest observed: 2026-10-20
Americas
🇺🇸 United StatesOfficialapproval, expedited programmes, confirmatory/withdrawal; not coveragecurrent page / AA quarterly data through 2026-03-31Latest observed: 2026
🇺🇸 United StatesOfficialNCD/LCD/benefit and reasonable-necessary boundarycurrentLatest observed: 2026
🇺🇸 United StatesOfficialASP reporting/payment; exact product file must be checked2026 quarterly filesLatest observed: 2026
🇺🇸 United StatesOfficialcoding/payment status, not coverageQ2 2026/current OPPS materialsLatest observed: 2026
🇺🇸 United StatesOfficialP&T, review, protected classes and formulary standardsCY2026/current manualLatest observed: 2026
🇺🇸 United StatesOfficialMFP selection/price/effectuation; selected products onlyfirst MFP effective 2026-01-01Latest observed: 2026-07
🇺🇸 United StatesOfficial2026 benefit/liability and selected-drug formulary rule2025-04-07 / CY2026Latest observed: 2025-04-07
🇺🇸 United StatesOfficialNDRA, coverage, AMP/Best Price/URA; state implementation separatecurrent programme and 2026 releasesLatest observed: 2026
🇺🇸 United StatesOfficialstate PDL/PA/rebate variation; named state must be checkedcurrent through 2026Latest observed: 2026-05
🇺🇸 United StatesOfficialPPA and ceiling obligations; not payer coveragecurrentLatest observed: 2026
🇺🇸 United StatesOfficialofficial market investigation evidence; not a universal contract rule2024 interim / 2025 second reportLatest observed: 2025-01
🇺🇸 United StatesOfficialVA statutory agreements/FCP; exact covered drug and contract needed2026 annual guidanceLatest observed: 2026
🇺🇸 United StatesOfficialWAC is list price excluding reductions; older explanatory rule, definition currentstatutory definitionLatest observed: current statute
🇺🇸 United StatesOfficialAMP/FUL/acquisition-cost background; current releases supersede specificsCMS-2345-FCLatest observed: current framework
🇺🇸 United StatesOfficialshows ERISA plan/PBM boundary; proposal is not final ruleproposed PBM disclosure rule, 2026-01-30Latest observed: 2026-02-27
For education only — not regulatory, pricing or legal advice.